https://www.selleckchem.com/pr....oducts/vps34-inhibit
The clinical context for using blood eosinophil (EOS) counts as treatment-response biomarkers in asthma and chronic obstructive pulmonary disease (COPD) requires better understanding of EOS distributions and ranges. We describe EOS distributions and ranges published in asthma, COPD, control (non-asthma/COPD) and general populations. We conducted a comprehensive literature review and meta-analysis of observational studies (Jan 2008 to Nov 2018) that included EOS counts in asthma, severe asthma, COPD, control and general populat
Like
Comment
Share
